GlassScriptPhysician profile
Jaime Da Silva Arocho
NPI 1720062144
$3,846.83
in general payments reported to CMS, 2019-2025
19 companies · $740 in 2025
The $740 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $72.38 · 2021: $236 · 2022: $516 · 2023: $1,044 · 2024: $965 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,740 · Education: $9.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,739.78 |
| Education | $9.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $919.94 | 2022-2025 | Nxstage System One, Liberty Select Cycler |
| Astrazeneca Pharmaceuticals LP | $722.64 | 2019-2025 | Lokelma, Farxiga |
| Fresenius USA Marketing, INC. | $324.03 | 2019-2024 | 2008k @ Home, 2008t Bluestar Hemodialysis Machine |
| Horizon Therapeutics Plc | $250.00 | 2022-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.88 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $202.79 | 2022-2024 | |
| Calliditas Therapeutics US INC. | $198.47 | 2024-2025 | Tarpeyo |
| Medtronic, INC. | $127.29 | 2025 | Ellipsys Vascular Access System |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2023 | Jynarque |
| Mallinckrodt Hospital Products INC. | $117.10 | 2022-2023 | Acthar |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $116.82 | 2023-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $114.84 | 2019-2021 | |
| Travere Therapeutics, INC. | $108.24 | 2023 | |
| Boston Scientific Corporation | $83.48 | 2022 | |
| Janssen Pharmaceuticals, INC | $74.73 | 2023-2024 | Xarelto |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $48.76 | 2019 | |
| Lilly USA, LLC | $26.09 | 2025 | Jardiance |
| Bayer Puerto Rico INC. | $23.37 | 2023 | Kerendia |
| Glaxosmithkline, LLC. | $13.36 | 2023 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Da Silva Arocho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.